Novartis at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Novartis takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1059. Its program centres on radioligand therapy aimed at prostate-specific membrane antigen in prostate cancer, now and in the future. It also covers tailoring CDK4/6 inhibitor treatment to the risk of recurrence in hormone receptor-positive, HER2-negative breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Swiss pharmaceutical company whose oncology medicines include ribociclib for breast cancer and radioligand therapies. | Booth Exhibiting at Booth 1059 Satellite Sat Oct 24 13:00–14:30 Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Satellite Mon Oct 26 13:00–14:30 |
Instantly find 20 buyers from Novartis
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction